Valneva SE ADR

Valneva SE ADR

Yahoo Finance • 26 days ago

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate,... Full story

Yahoo Finance • last month

The Bull Case For Pfizer (PFE) Could Change Following New COVID And Lyme Vaccine Milestones - Learn Why

In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 had its... Full story

Yahoo Finance • 2 months ago

Pfizer (PFE) Stock Looks Reasonable On Returns But Stretched On Earnings

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a... Full story

Yahoo Finance • 2 months ago

Valneva GAAP EPS of -€0.35, revenue of €65.84M; reaffirms FY 2026

* Valneva press release [https://seekingalpha.com/pr/20617691-valneva-reports-half-year-2026-financial-results-and-provides-corporate-updates] (VALN [https://seekingalpha.com/symbol/VALN]): 1H GAAP EPS of -€0.35. * Revenue of €65.84M (... Full story

Yahoo Finance • 4 months ago

Valneva Announces Successful Outcome of its Annual General Meeting

Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that shareholders approved all resolutions re... Full story

Yahoo Finance • 4 months ago

Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale

Le Dr Gerd Zettlmeissl est nommé président du conseil d’administration Lyon (France), le 25 juin 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que toutes les résolutions... Full story

Yahoo Finance • 4 months ago

Valneva Announces Availability of Documentation for its Annual General Meeting

Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting”) to be held on June... Full story

Yahoo Finance • 4 months ago

Valneva annonce la mise à disposition de la documentation relative à son Assemblée Générale annuelle

Lyon (France), le 4 juin 2026 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins (« la Société »), a annoncé aujourd’hui la mise à disposition de la documentation relative à son Assemblée Générale ann... Full story

Yahoo Finance • 5 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomla... Full story

Yahoo Finance • 6 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomla... Full story

Yahoo Finance • 6 months ago

Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data

Valneva SE (NASDAQ:VALN) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3... Full story

Yahoo Finance • 7 months ago

Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over... Full story

Yahoo Finance • 7 months ago

Valneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 Trial; Shows More Than 70% Efficacy

(RTTNews) - Valneva SE (VALN) saw its stock drop sharply, even as the company and partner Pfizer announced that their Lyme disease vaccine candidate demonstrated more than 70% efficacy in a large Phase 3 study. Lyme disease, spread throug... Full story

Yahoo Finance • 7 months ago

Traders Digest Signs of Easing Middle East Tensions as US Equity Futures Rise Pre-Bell

US equity futures were up ahead of Monday's opening bell after President Donald Trump said he has or PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 months ago

Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR

Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus.Le candidat vaccin a été bien toléré, sans problème de sécurité identifié... Full story

Yahoo Finance • 7 months ago

Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

This article first appeared on GuruFocus. Release Date: March 18, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Valneva SE (INRLF) reported total revenues exce... Full story

Yahoo Finance • 7 months ago

Valneva reports FY results; gives FY26 outlook

* Valneva press release [https://seekingalpha.com/pr/20441902-valneva-reports-full-year-2025-audited-consolidated-financial-results] (VALN [https://seekingalpha.com/symbol/VALN]): FY Revenue of €174.7M (+3.0% Y/Y), including €157.9 milli... Full story

Yahoo Finance • 7 months ago

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing and a 21% reductio... Full story

Yahoo Finance • 7 months ago

Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025

Chiffre d’affaires de 174,7 millions d’euros, conforme aux prévisions, dont 157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au refinancement réussi de... Full story

Yahoo Finance • 7 months ago

Valneva gibt die konsolidierten geprüften Finanzergebnisse für das Gesamtjahr 2025 bekannt

Der Gesamtumsatz von 174,7 Millionen Euro entspricht den Prognosen, davon 157,9 Millionen Euro aus Produktverkäufen Starke Liquiditätsposition zum Jahresende von 109,7 Millionen Euro, verbesserte finanzielle Flexibilität nach erfolgreiche... Full story